Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led by OrbiMed, with participation from Hankang Capital, Sequoia China, and a globally renowned corporate venture fund. Proceeds will accelerate global clinical development of PTX‑912, a first‑in‑class PD‑1/IL‑2 fusion protein, and advance several preclinical pipelines.
Corporate Milestone
Item
Detail
Company
Proviva Therapeutics
Round
Series A+
Amount
Over USD 30 million
Lead Investor
OrbiMed
Co‑Investors
Hankang Capital, Sequoia China, Corporate Venture Fund
Use of Proceeds
Accelerate PTX‑912 global clinical development; advance preclinical pipelines
Founded
Not disclosed (post‑Series A+)
Drug Profile – PTX‑912
Mechanism: First‑in‑class fusion protein combining PD‑1 antibody with IL‑2 prodrug
Dual Action:PD‑1 blockade plus TME‑selective IL‑2 signaling activation
Innovation: Designed to enhance anti‑tumor immune response while reducing severe systemic toxicity associated with IL‑2 drugs
Current Status: Phase I dose‑escalation trial; preliminary data show good safety/tolerability and confirmed Partial Response (cPR) in NSCLC patients
Technology Platform
Feature
Description
PD‑1 Blockade
Releases immune brakes on T‑cells
IL‑2 Prodrug
Activates IL‑2 pathway selectively in tumor microenvironment
Toxicity Reduction
Minimizes systemic IL‑2 exposure vs. traditional IL‑2 therapy
Clinical Data
cPR observed in NSCLC; dose escalation ongoing
Market Impact & Outlook
Metric
Value
Global Oncology Market
$250 billion (2024)
PD‑1/PD‑L1 Market
$35 billion (2024)
IL‑2 Therapy Market
$500 million (niche due to toxicity)
Combination Therapy Growth
15% CAGR (2024‑2030)
Peak Sales Potential (PTX‑912)
$800 million‑1.2 billion if approved across solid tumors
Competition: No approved PD‑1/IL‑2 fusions globally; BMS, Roche exploring similar concepts pre‑clinically
Next Catalyst: Phase Ib expansion cohort data expected Q3 2026
Forward‑Looking Statements This brief contains forward‑looking statements regarding Proviva’s financing utilization, PTX‑912 development, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, competitive dynamics, and regulatory approvals.-Fineline Info & Tech
By Fineline Cube 